Merck KGaA, Darmstadt, Germany: Ovarian Neoplasms trials

The registry lists 10 Ovarian Neoplasms studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 4Phase 2 5Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsRecruitingNCT07360314Phase 1
• Nirogacestat in Ovarian Granulosa Cell TumorsCompletedNCT05348356Phase 2Results posted
• Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian CancerCompletedNCT03704467Phase 1Results posted
• Trial of Pimasertib With SAR245409 or Placebo in Ovarian CancerCompletedNCT01936363Phase 2Results posted
• EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver MetastasesCompletedNCT00848510Phase 1Results posted
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2
• M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruitingNCT06421935Phase 1
• Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
• Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.WithdrawnNCT00408967Phase 2
• A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian CancerCompletedNCT00073541Phase 2